HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 1 matching record:

Displaying record number 55662

HXB2 Location  gp160(577-587)   gp160 Epitope Map
View variants at this location
Epitope QTRVLAIERYL   Epitope Alignment
Variants
QaRVLAIERYL   susceptible form
QTRVLAmERYL   non-susceptible form
QTRVLAlERYL   susceptible form
QTRVLAvERYL   susceptible form
QaRVLAmERYL   susceptible form
Epitope Name QL11
Species (MHC/HLA human(B*5801, B*5802)

Variant Details

Showing all: 5 variant(s).


Variant ID.  1331
Epitope Seq.  QTRVLAIERYL
Variant Seq.  QaRVLAIERYL
Mutations T/A
Epitope Location T2A
HXB2 Location T578A
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Sequence
Note This T2A polymorphism was not statistically associated with HLA-B*5802 expression. Of 42 HLA-B*5802+ subjects, 5 responders to the index epitope QL11 and 19 nonresponders to QL11, carried the variant. 38/74 (51.4%) B*5802 negative subjects also carried the variant. Nonresponders to the QL11 did not respond to T2A variant, but responders to QL11 showed broad cross-recognition to the variant indicating lack of functional escape.


Variant ID.  1332
Epitope Seq.  QTRVLAIERYL
Variant Seq.  QTRVLAmERYL
Mutations I/M
Epitope Location I7M
HXB2 Location I583M
Mutation Type NSF: non-susceptible form
Method CD8 T-cell Elispot - IFNy, Sequence
Note This polymorphism was not statistically associated with HLA-B*5802 expression. Of 42 HLA-B*5802+ subjects, no responders to the index epitope QL11 and 3 nonresponders to QL11, carried the variant. 1/74 (1.4%) B*5802 negative subjects also carried the variant. The nonresponders to the QL11 did not respond to this variant.


Variant ID.  1333
Epitope Seq.  QTRVLAIERYL
Variant Seq.  QTRVLAlERYL
Mutations I/L
Epitope Location I7L
HXB2 Location I583L
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Sequence
Note This I7L polymorphism was not statistically associated with HLA-B*5802 expression. Of 42 HLA-B*5802+ subjects, 2 responders to the index epitope QL11 and no nonresponders to QL11, carried the variant. 1/74 (1.4%) B*5802 negative subjects also carried the variant. Nonresponders to the QL11 did not respond to I7L variant, but responders to QL11 showed broad cross-recognition to the variant indicating lack of functional escape.


Variant ID.  1334
Epitope Seq.  QTRVLAIERYL
Variant Seq.  QTRVLAvERYL
Mutations I/V
Epitope Location I7V
HXB2 Location I583V
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Sequence
Note This polymorphism was not statistically associated with HLA-B*5802 expression. Of 42 HLA-B*5802+ subjects, 2 responders to the index epitope QL11 and no nonresponders to QL11, carried the variant. No (0%) B*5802 negative subjects carried the variant. Nonresponders to QL11 did not respond to this variant, but responders to QL11 showed broad cross-recognition to this variant indicating lack of functional escape.


Variant ID.  1336
Epitope Seq.  QTRVLAIERYL
Variant Seq.  QaRVLAmERYL
Mutations T/A I/M
Epitope Location T2A I7M
HXB2 Location T578A I583M
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Sequence
Note This T2A, I7L polymorphism was not statistically associated with HLA-B*5802 expression. Of 42 HLA-B*5802+ subjects, 2 responders to the index epitope QL11 and 1 nonresponder to QL11, carried double variants at these positions. 5/74 (6.7%) B*5802 negative subjects also carried double variants at these positions. Nonresponders to the QL11 did not respond to T2A variant, but responders to QL11 showed broad cross-recognition to the variant indicating lack of functional escape.

References

Ngumbela2008 K. C. Ngumbela, C. L. Day, Z. Mncube, K. Nair, D. Ramduth, C. Thobakgale, E. Moodley, S. Reddy, C. de Pierres, N. Mkhwanazi, K. Bishop, M. van der Stok, N. Ismail, I. Honeyborne, H. Crawford, D. G. Kavanagh, C. Rousseau, D. Nickle, J. Mullins, D. Heckerman, B. Korber, H. Coovadia, P. Kiepiela, P. J. R. Goulder, and B. D. Walker. Targeting of a CD8 T Cell Env Epitope Presented by HLA-B*5802 Is Associated with Markers of HIV Disease Progression and Lack of Selection Pressure. AIDS Res. Hum. Retroviruses, 24(1):72-82, Jan 2008. PubMed ID: 18275350. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Operated by Los Alamos National Security, LLC, for the U.S. Department of Energy's National Nuclear Security Administration
Copyright © 2006-2017 LANS LLC All rights reserved | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health